HAE
$57.76
Haemonetics
$.12
.21%
Earnings Details
3rd Quarter December 2025
Thursday, February 5, 2026 6:00:00 AM
Tweet Share Watch
Summary

Haemonetics Narrows Guidance

Haemonetics (HAE) reported 3rd Quarter December 2025 earnings of $1.31 per share on revenue of $339.0 million. The consensus earnings estimate was $1.27 per share on revenue of $334.2 million. Revenue fell 2.7% compared to the same quarter a year ago.

The company said it expects fiscal 2026 earnings of $4.90 to $5.00 per share. The company's previous guidance was earnings of $4.80 to $5.00 per share, and the current consensus earnings estimate is $4.93 per share for the year ending March 31, 2026.

Haemonetics Corp is a healthcare company that provides blood management solutions to its customers. It serves three markets: manufacturers of plasma derived pharmaceuticals, blood collectors, and hospitals.

Results
Reported Earnings
$1.31
Earnings Whisper
-
Consensus Estimate
$1.27
Reported Revenue
$339.0 Mil
Revenue Estimate
$334.2 Mil
Growth
Earnings Growth
Revenue Growth
Power Rating
Grade
Earnings Release

Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website

Financial release and supplemental presentation accessible online

BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 5, 2026.

Conference Call and Webcast Information:

  • Registration: Click here to register. Upon registration, participants will receive dial-in details and a personalized PIN. While not required, joining 10 minutes prior to the event start time is recommended.
  • Live webcast: Access here or through the Investor Relations section of the Haemonetics website.

A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on February 5, 2026 and will remain accessible for one year via the webcast link above.

Earnings Materials:
Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast:

ABOUT HAEMONETICS

Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:


Olga Guyette, Vice President-Investor Relations & Treasury

David Trenk, Manager-Investor Relations

(781) 356-9763 

(203) 733-4987

olga.guyette@haemonetics.com


david.trenk@haemonetics.com


Media Contact:


Josh Gitelson, Sr. Director-Global Communications


(781) 356-9776


josh.gitelson@haemonetics.com 


Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-corporation-announces-third-quarter-fiscal-2026-financial-results-available-on-investor-relations-website-302679292.html

SOURCE Haemonetics Corporation